Edwards Lifesciences Corp. Receives Buy Rating from Canaccord Genuity (EW)
Edwards Lifesciences Corp. (NYSE:EW)‘s stock had its “buy” rating reiterated by Canaccord Genuity in a research note issued on Tuesday, AR Network reports. They currently have a $90.00 price target on the stock. Canaccord Genuity’s price target indicates a potential upside of 24.81% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at RBC Capital raised their price target on shares of Edwards Lifesciences Corp. (NYSE:EW) from $72.00 to $75.00 in a research note to investors on Tuesday. They now have a “sector perform” rating on the stock. Separately, analysts at Zacks upgraded shares of Edwards Lifesciences Corp. (NYSE:EW) from an “underperform” rating to a “neutral” rating in a research note to investors on Thursday, August 29th. They now have a $74.00 price target on the stock. Finally, analysts at Northland Capital Partners upgraded shares of Edwards Lifesciences Corp. (NYSE:EW) from a “market perform” rating to an “outperform” rating in a research note to investors on Thursday, July 18th. They now have a $74.00 price target on the stock.
One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $80.69.
Shares of Edwards Lifesciences Corp. (NYSE:EW) traded up 0.54% on Tuesday, hitting $72.11. The stock had a trading volume of 593,443 shares. Edwards Lifesciences Corp. has a 52 week low of $62.34 and a 52 week high of $110.79. The stock has a 50-day moving average of $71.50 and a 200-day moving average of $73.21. The company has a market cap of $8.096 billion and a P/E ratio of 20.96.
Edwards Lifesciences Corp. (NYSE:EW) last released its earnings data on Thursday, July 25th. The company reported $0.82 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.76 by $0.06. The company had revenue of $517.20 million for the quarter, compared to the consensus estimate of $514.59 million. During the same quarter in the prior year, the company posted $0.57 earnings per share. The company’s quarterly revenue was up 7.3% on a year-over-year basis. Analysts expect that Edwards Lifesciences Corp. will post $3.07 EPS for the current fiscal year.
In other Edwards Lifesciences Corp. news, VP Huimin Wang sold 4,850 shares of the stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $71.24, for a total value of $345,514.00. Following the transaction, the vice president now directly owns 31,337 shares in the company. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.